First company to share raw AMR surveillance data




AMR surveillance


Pfizer is the first company to share raw data on the spread of resistance so that third parties can explore the potential for further research.



Surveillance data helps governments, public health authorities and healthcare professionals to measure and respond to infections, analyse local trends and prioritise objectives in stewardship policies. By making data available publicly, companies can help provide valuable insights into where resistance to specific medicines is occurring. This can lead to better treatment choices, by helping doctors determine which medicines are likely to be ineffective because of resistance. Specifically, by sharing the raw data from companies’ surveillance programmes, third-party researchers can explore the potential for further research, beyond the specific questions asked by the companies themselves.

How does Pfizer lead in this area? 
Through its Antimicrobial Testing Leadership and Surveillance (ATLAS) programme, Pfizer monitors the resistance of pathogens, including nine priority pathogens, against its marketed antibacterial products and those in development. ATLAS was established in 2004 and now operates in 73 countries. The company demonstrates best practice by being the first company in scope to share the raw data from ATLAS on the AMR Register, an open-access data platform founded by Open Data Institute and Wellcome Trust. Recent uses of data include an interactive web app (recognised by 2019’s Wellcome Data Re-Use Prizes), which visualises resistance rates to antibacterial products for common infections, and helps healthcare professionals to prescribe appropriately.

Learn more

View our detailed overview of each company’s performance

Back to top |